Radionenhancer | Nano Publications https://bibliography.nanobiotix.com/fr/ Navigate through all Nanobiotix publications online Wed, 25 May 2022 09:24:32 +0000 fr-FR hourly 1 https://wordpress.org/?v=6.0 https://bibliography.nanobiotix.com/wp-content/uploads/2019/11/cropped-n-icon-512x512-32x32.png Radionenhancer | Nano Publications https://bibliography.nanobiotix.com/fr/ 32 32 2017 – Immunotherapy Workshop https://bibliography.nanobiotix.com/fr/2017-immunotherapy-workshop/ https://bibliography.nanobiotix.com/fr/2017-immunotherapy-workshop/#respond Mon, 19 Jun 2017 07:45:44 +0000 http://bibliography.nanobiotix.com/?p=1196/ Radiotherapy (RT) has proven its ability to function like an in-situ vaccine, showing potential for successful combination with immunotherapeutic agents. Hafnium oxide nanoparticle (HfO2-NP), undergoing clinical trials for enhancing RT, was designed as high electron density material at the nanoscale. HfO2-NPs are taken up by cancer cells and, when exposed to RT, locally increase the radiation dose deposit, triggering more cancer cells death when compared to RT. We hypothesized that HfO2-NP+RT could trigger an enhanced immune response when compared to RT, both in preclinical and clinical settings.

The post 2017 – Immunotherapy Workshop first appeared on Nano Publications.]]>

Authors

Galon J.1, Laé M.2, Papai Z.3, Rochaix P.4, Mangel L. C.5, Hermitte F.6, Sapi Z.7, Delannes M.4, Tornoczky T.5, Vincent-Salomon A.2, Paris S.8, Pottier A.8, Bonvalot S.2

1 – INSERM, Paris, France
2 – Institut Curie, Paris, France
3 – Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary
4 – Institut Universitaire du Cancer Toulouse, Toulouse, France
5 – Pecs University, Pecs, Hungary
6 – HalioDX, Marseille, France
7 – Semmelweis University, Budapest, Hungary
8 – Nanobiotix, Paris, France

Summary

Immunotherapy Workshop: Bethesda, MD, June 15-16, 2017

Radiotherapy (RT) has proven its ability to function like an in-situ vaccine, showing potential for successful combination with immunotherapeutic agents. Hafnium oxide nanoparticle (HfO2-NP), undergoing clinical trials for enhancing RT, was designed as high electron density material at the nanoscale. HfO2-NPs are taken up by cancer cells and, when exposed to RT, locally increase the radiation dose deposit, triggering more cancer cells death when compared to RT. We hypothesized that HfO2-NP+RT could trigger an enhanced immune response when compared to RT, both in preclinical and clinical settings.

The post 2017 – Immunotherapy Workshop first appeared on Nano Publications.]]> https://bibliography.nanobiotix.com/fr/2017-immunotherapy-workshop/feed/ 0 2017 – AACR Abstract – NBTXR3 combination with cisplatin in vivo and in vitro https://bibliography.nanobiotix.com/fr/2017-aacr-abstract-nbtxr3-combination-with-cisplatin-in-vivo-and-in-vitro/ https://bibliography.nanobiotix.com/fr/2017-aacr-abstract-nbtxr3-combination-with-cisplatin-in-vivo-and-in-vitro/#respond Wed, 01 Mar 2017 10:07:40 +0000 http://localhost:8888/bibliography/?p=778 Combination of NBTXR3 and cisplatin has been evaluated in vitro and in vivo. No specific toxicity was observed for the cells exposed only to NBTXR3. For the combined treatment, a marked and enhanced cell destruction when compared to the single agent. In vivo, NBTXR3 combined with low dose of cisplatin delayed tumor growth when compared to single agent CDDP in combination with RT.

NBTXR3 is intended to be injected in the tumors. Spilling in the circulation may occur during product administration or, as expected, during tumor destruction, leading to steady trapping of NPs in the reticulo-endothelial system (liver and spleen). Clinically, it is unknown whether patients, previously treated with NPs, may show toxic signs when NPs are exposed (activation) to diagnosis imaging (computed tomography(CT)) of the liver.

The post 2017 – AACR Abstract – NBTXR3 combination with cisplatin in vivo and in vitro first appeared on Nano Publications.]]>

Authors

Agnès Pottier1, Sonia Vivet1, Sébastien Paris1, Bo Lu2
1 – Nanobiotix, Paris, France
2 – Thomas Jefferson University, Philadelphia, PA

Summary

Combination of NBTXR3 and cisplatin has been evaluated in vitro and in vivo. No specific toxicity was observed for the cells exposed only to NBTXR3. For the combined treatment, a marked and enhanced cell destruction when compared to the single agent. In vivo, NBTXR3 combined with low dose of cisplatin delayed tumor growth when compared to single agent cisplatin in combination with radiotherapy.

The post 2017 – AACR Abstract – NBTXR3 combination with cisplatin in vivo and in vitro first appeared on Nano Publications.]]> https://bibliography.nanobiotix.com/fr/2017-aacr-abstract-nbtxr3-combination-with-cisplatin-in-vivo-and-in-vitro/feed/ 0 2015 – Metals as radio-enhancers in oncology – Pottier et al. https://bibliography.nanobiotix.com/fr/2015-metals-as-radio-enhancers-in-oncology-pottier-et-al/ https://bibliography.nanobiotix.com/fr/2015-metals-as-radio-enhancers-in-oncology-pottier-et-al/#respond Tue, 14 Feb 2017 15:25:15 +0000 http://localhost:8888/bibliography/2017/02/14/2015-metals-as-radio-enhancers-in-oncology-pottier-et-al/ Radio-enhancers, metal-based nanosized agents, could play a key role in oncology. They may unlock the potential of radiotherapy by enhancing the radiation dose deposit within tumors when the ionizing radiation source is ‘on’, while exhibiting chemically inert behavior in cellular and subcellular systems when the radiation beam is ‘off’. Important decision points support the development of these new type of therapeutic agents originated from nanotechnology. Here, we discuss from an industry perspective, the interest of developing radio-enhancer agents to improve tumor control, the relevance of nanotechnology to achieve adequate therapeutic attributes, and present some considerations for their development in oncology.

The post 2015 – Metals as radio-enhancers in oncology – Pottier et al. first appeared on Nano Publications.]]>

Authors

Agnès Pottier1, Elsa Borghi1, Laurent Levy1
1 – Nanobiotix, Paris, France

0006-291X/© 2015 Published by Elsevier Inc.
https://dx.doi.org/10.1016/j.bbrc.2015.09.027
https://www.sciencedirect.com/science/journal/0006291X

Summary

Radio-enhancers, metal-based nanosized agents, could play a key role in oncology. They may unlock the potential of radiotherapy by enhancing the radiation dose deposit within tumors when the ionizing radiation source is ‘on’, while exhibiting chemically inert behavior in cellular and subcellular systems when the radiation beam is ‘off’. Important decision points support the development of these new type of therapeutic agents originated from nanotechnology. Here, we discuss from an industry perspective, the interest of developing radio-enhancer agents to improve tumor control, the relevance of nanotechnology to achieve adequate therapeutic attributes, and present some considerations for their development in oncology.

The post 2015 – Metals as radio-enhancers in oncology – Pottier et al. first appeared on Nano Publications.]]> https://bibliography.nanobiotix.com/fr/2015-metals-as-radio-enhancers-in-oncology-pottier-et-al/feed/ 0 2014 – NBTXR3 concept and dose enhancement – Marill et al. https://bibliography.nanobiotix.com/fr/2014-nbtxr3-concept-and-dose-enhancement-marill-et-al/ https://bibliography.nanobiotix.com/fr/2014-nbtxr3-concept-and-dose-enhancement-marill-et-al/#respond Mon, 06 Feb 2017 08:45:26 +0000 http://localhost:8888/bibliography/2017/02/06/2014-nbtxr3-concept-and-dose-enhancement-marill-et-al/ Hafnium oxide, NBTXR3 nanoparticles were designed for high dose energy deposition within cancer cells when exposed to ionizing radiation. The purpose of this study was to assess the possibility of predicting the in vitro the biological effect of NBTXR3 nanoparticles when exposed to ionizing radiation. Cellular uptake of NBTXR3 nanoparticles was assessed in a panel of human cancer cell lines (radioresistant and radiosensitive) by transmission electron microscopy. The radioenhancement of NBTXR3 nanoparticles was measured by the clonogenic survival assay.

The post 2014 – NBTXR3 concept and dose enhancement – Marill et al. first appeared on Nano Publications.]]>

Authors

Julie Marill1*, Naeemunnisa Mohamed Anesary1, Ping Zhang1, Sonia Vivet1, Elsa Borghi1, Laurent Levy1, Agnes Pottier1
1 – Nanobiotix, 60 rue de wattignies, 75012 Paris, France
*Corresponding author

Summary

Background: Hafnium oxide, NBTXR3 nanoparticles were designed for high dose energy deposition within cancer cells when exposed to ionizing radiation. The purpose of this study was to assess the possibility of predicting the in vitro the biological effect of NBTXR3 nanoparticles when exposed to ionizing radiation.

Methods: Cellular uptake of NBTXR3 nanoparticles was assessed in a panel of human cancer cell lines (radioresistant and radiosensitive) by transmission electron microscopy. The radioenhancement of NBTXR3 nanoparticles was measured by the clonogenic survival assay.

Results: NBTXR3 nanoparticles were taken up by cells in a concentration dependent manner, forming clusters in the cytoplasm. Differential nanoparticle uptake was observed between epithelial and mesenchymal or glioblastoma cell lines. The dose enhancement factor increased with increase NBTXR3 nanoparticle concentration and radiation dose. Beyond a minimum number of clusters per cell, the radioenhancement of NBTXR3 nanoparticles could be estimated from the radiation dose delivered and the radiosensitivity of the cancer cell lines.

Conclusions: Our preliminary results suggest a predictable in vitro biological effect of NBTXR3 nanoparticles exposed to ionizing radiation.

The post 2014 – NBTXR3 concept and dose enhancement – Marill et al. first appeared on Nano Publications.]]> https://bibliography.nanobiotix.com/fr/2014-nbtxr3-concept-and-dose-enhancement-marill-et-al/feed/ 0